Meet Dr. Dropin, the Norwegian startup disrupting health care with €19.20 million

The market for telehealth and telemedicine is ever-growing, especially in the post COVID world. Bullish on the segment, Finnish digital health company VideoVisit was acquired by Dutch software investor Main Capital Partners and Munich-based healthcare provider Avi Medical wrapped up €50 million in a Series B funding in the last few days.

Disrupting health care in Norway, digi-physical healthcare operator Dr.Dropin has now raised €19.20 million in funding to expand its physical network of clinics and scale up digital solutions and tech platform across the country and globally, too. The round was led by venture capital firms SHS Capital and Yabeo with participation from existing investors Andenes Ventures and Stenshagen Invest.

Founded in 2017 in Oslo, the platform aims to democratise the private healthcare market by making instant access to care services available to the public at an affordable price, both physically and digitally. 

Its one-stop shop simplifies the healthcare service by offering services that range from general medicine to specialist health services, including dermatologists, physical therapists and psychologists. The company says approximately 25% of consultations are conducted digitally on the platform.

Dr. Daniel Sørli, CEO, Dr.Dropin said: “With this substantial investment, we look forward to further expanding our services outside Norway, and providing everyone ranging from private individuals to public entities with modern and effective healthcare driven by the latest medical research and technology.”

Dr. Cornelius Maas, partner, SHS Capital added: “Dr.Dropin is an exciting Nordic healthcare provider with a strong technological foundation which we find interesting. At SHS we are passionate about building European healthcare champions, and looking at Dr.Dropin’s track record and their team of highly skilled medical and business professionals we are confident that the company is well positioned to expand into the European market and be a substantial competitor to the already established healthcare providers across Europe.”